Pharmaceutical giant Eli Lilly's weight loss drug tirzepatide was found to reduce the risk of developing Type 2 diabetes by 94% among people with excess weight, according to a study released yesterday.
The three-year study is the longest completed study of the drug and involved observing the effects of the weekly injectable in more than 1,000 patients with prediabetes who were obese or overweight. The study showed those who took the highest weekly dose at 15 mg saw a nearly 23% reduction in body weight on average and a 94% reduced risk of developing diabetes compared with prediabetics who took a placebo and lost 2% of their body weight on average. See a diabetes overview here.
Tirzepatide is the active ingredient in Eli Lilly's weight loss drug Zepbound and its diabetes version Mounjaro—both of which have gained popularity due to their aid in weight loss. Eli Lilly is the world's most valuable pharmaceutical drugmaker with a $900B market cap and has seen its shares rise over 60% this year.
Opmerkingen